Political and health leaders have signed and adopted the Nagasaki Outcomes Statement, calling for accelerated R&D, access, and delivery for neglected tropical d 4 July 2023
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.